AstraZeneca Partners with Mankind to Distribute Asthma Drugs in India

AstraZeneca Partners with Mankind to Distribute Asthma Drugs in India

By, Admin 12 March 2024

AstraZeneca Pharma India, Mankind partner to accelerate access to asthma medicine in India 

India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths. It highlights a clear scope of improving the way asthma is managed in the country.  AstraZenecaPharma India Limited and Mankind Pharma Limited entered into an agreement for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India. 

IPR

AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder (MAH) and import license.

India’s Contribution

  • India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths. 
  • It highlights a clear scope of improving the way asthma is managed in the country. ""The partnership with Mankind Pharma presents an opportunity to accelerate access and maximize the potential of our asthma drug as well as the turbuhaler which is a simple device, efficient in consistently delivering a higher proportion of respirable particles than the other devices. As much as we are excited to bring innovative medicine to India fast, we are equally invested on improving access strategically in the country,"" said Dr. Sanjeev Panchal, Country President and Managing Director, AstraZeneca India.

Mankind on Agreement

  • Commenting on the agreement with AstraZeneca India, Atish Majumdar, Sr. President – Sales & Marketing, Mankind Pharma Limited said We are excited to partner with AstraZeneca to make their innovative therapy flagship brand Symbicort, a global standard in treating Asthma. 
  • Symbicort's dual mechanism of action and ease of use in a single inhaler can greatly help patients manage these conditions and improve their quality of life. 
  • Through our field forces’ extensive outreach, we hope to strengthen access across urban and rural markets. With our shared goal to enable better patient outcomes, I see this collaboration as strategic in more ways than one. 
  • We believe such credible partnerships that widen availability of globally established medicines in India exemplify our ethos of putting patients first while ensuring value.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!